Rheumatoid arthritis (disorder)
PEAC: Pathobiology of Early Arthritis Cohort
Year Started: 2008
Prospective, observational study in patients with early symptomatic inflammatory arthritis (http://www.peac-mrc.mds.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at two timepoints - Baseline & Follow-up (6 month), please note figures for baseline samples are represented (6 month sample availability on request). Demographic & clinical data is available & collected at 5 timepoints over a 1-year follow-up period (Baseline, 3, 6, 9 & 12 months). Current recruitment status for Rheumatoid Arthritis cohort is 214 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 51 - 75% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
| Urine | -60°C to -85°C | N/A | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
R4-RA: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA
Year Started: 2013
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase IV study (http://www.r4ra-nihr.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Recruitment status for this study is 164 patients.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
STRAP: Stratification of Biologic Therapies for RA by Pathobiology. A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab.
Year Started: 2015
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase III study (http://www.matura-mrc.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Current recruitment status for this study is 200 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Sjögren's syndrome (disorder)
TRACTISS: A randomized double blind placebo controlled clinical TRial of anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome
Year Started: 2011
A multi-centre, randomised, double-blind, placebo controlled, phase III trial in patients with primary Sjögren’s syndrome with fatigue, oral dryness. Males and female recruited between 18 and 80 years of age with an AECG diagnosis of Primary Sjögren’s Syndrome. Biological samples (salivary gland tissue & fluids) collected at multiple timepoints (details available on request) over a 48 week follow-up period; please note figures for baseline samples are represented (availability of samples from other timepoints on request). Recruitment status for this study is 136 patients.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 3 - 6 months |
| Followup records | 3 - 6 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 3 - 6 months |
| Treatment records | 3 - 6 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 11 - 25% | |
| Saliva | -60°C to -85°C | N/A | Affected | 11 - 25% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 11 - 25% |